1-2 of 2
Ing S Tiong, MBChB
Close
Sort by
Journal Articles

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Ing S Tiong, MBChB,FRACP,FRCPA, Richard Dillon, MA, PhD MRCP, FRCPath, Adam Ivey, BSc, MSc, PhD, Tse-Chieh Teh, MBBS,PhDFRACP, FRCPA, Catherine Vassili, RN,MN, Vanessa Roma Donati, RN, David Taussig, PhD MRCP, FRCPath, Nicola Potter, PhD, Jelena Jovanovic, PhD, Anju Kanda, MSc, Manohursingh Runglall, MSc, Nicola Foot, MSc, Mikel Valganon, PhD, Nigel H. Russell, MD, Kavita Raj, MD PhD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Andrew Grigg, Steven Knapper, DM, Andrew H. Wei, PhD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 2648.
https://doi.org/10.1182/blood-2019-123899
Published: 2019
Journal Articles

Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)

Andrew H Wei, MBBS,PhD, Chong Chyn Chua, MBBS, BMedSc, Ing S Tiong, MBChB, Chun Yew Fong, MBBS,FRACP,FRCPA, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Sarah Macraild, Jessica M Salmon, PhD, Adam Ivey, BSc, MSc, PhD, John Nguyen, Flora Yuen, BBiomedSc, Richard Hall, Shaun Fleming, Stefan K. Bohlander, MD, John Reynolds, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 333.
https://doi.org/10.1182/blood-2018-99-114243
Published: 2018